Aug. 18 at 6:34 PM
$HYFT – Regained Nasdaq compliance (Jul 7) + upcoming earnings.
$ZH – First profitable quarter, analysts bullish (
$4.70 PT).
$ESPR – NEXLETOL patent secured till 2040, strong moat.
Summary: Compliance win, profitable turnaround, and drug exclusivity make these solid long-term holds with asymmetric upside.